Table 8. Cellular immunity in survival group at admission and 2 weeks after admission.

	Normal range	After 2 weeks (n = 53)
CD3+ percentage, %	56–86	68.50(61.44, 75.51)
CD3+ count, /μL	723–2737	863.00(717.00, 1174.50)
<723/μL, n (%)		13 (24.53)
CD4+ percentage, %	33–58	41.61 (34.87, 46.65)
CD4+ count, /μL	404–1612	544.00 (448.00, 692.50)
<404/μL, n (%)		10 (18.87)
CD8+ percentage, %	13–39	24.08(18.30, 29.74)
CD8+ count, /μL	220–1129	301.00(240.50, 418.50)
<220/μL, n (%)		10(18.87)
CD4+/CD8+ ratio	0.9–2.0	1.73(1.35, 2.34)
<0.9, n (%)		2(3.77)
CD19+ percentage, %	5–22	11.03(8.41,13.35)
CD19+ count, /μL	80–616	140.00(103.00, 202.50)
<80/μL, n (%)		5(9.43)
CD16+56+ percentage, %	5–26	18.22(10.94, 22.09)
CD16+56+ count, /μL	84–724	217.00(143.50, 328.50)
<84/μL, n (%)		2(3.77)

* n = 53. Data shown are number (%) or median (interquartile range).